NCT02843061View on ClinicalTrials.gov

Combination of Rituximab and NK Immunotherapy for B Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2019

Conditions
B-cell Lymphoma Recurrent
Interventions
DRUG

Rituximab

BIOLOGICAL

NK immunotherapy

Each time 10 billion cells, 4 times in all,i.v.

Trial Locations (1)

510665

Cancer Institute in Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02843061 - Combination of Rituximab and NK Immunotherapy for B Lymphoma | Biotech Hunter | Biotech Hunter